While the top- and bottom-line numbers for PTC Inc. (PTC) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
PTC Inc. PTC reported third-quarter fiscal 2024 non-GAAP earnings per share (EPS) of 98 cents, down 1% on a year-over-year basis. The figure came in line with the Zacks Consensus Estimate.
PTC Inc. (NASDAQ:PTC ) Q3 2024 Results Earnings Conference Call July 31, 2024 5:00 PM ET Company Participants Matt Shimao - Head of Investor Relations Neil Barua - Chief Executive Officer Kristian Talvitie - Executive Vice President and Chief Financial Officer Conference Call Participants Siti Panigrahi - Mizuho Securities Tyler Radke - Citigroup Joe Vruwink - Robert W. Baird Stephen Tusa - J.P.
PTC Inc. (PTC) came out with quarterly earnings of $0.98 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.99 per share a year ago.
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Get a deeper insight into the potential performance of PTC Inc. (PTC) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
PTC's fiscal third-quarter performance is likely to have been driven by strong business pipeline activities across the PLM and CAD segments despite forex fluctuations.
PTC Inc. (PTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
PTC Inc. (PTC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
PTC Inc. provides lifecycle management software and services globally. The global PLM market is expected to grow at a CAGR of 8.6% from 2022 to 2030, with PTC competing with major industry players. PTC has shown revenue and earnings growth, and strong free cash flow.